Browse FCER1A

Summary
SymbolFCER1A
NameFc fragment of IgE, high affinity I, receptor for; alpha polypeptide
Aliases FCE1A; Fc IgE receptor, alpha polypeptide; Fc epsilon RI alpha-chain; Fc-epsilon RI-alpha; high affinity imm ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Single-pass type I membrane protein.
Domain PF13895 Immunoglobulin domain
Function

Binds to the Fc region of immunoglobulins epsilon. High affinity receptor. Responsible for initiating the allergic response. Binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators (such as histamine) responsible for the manifestations of allergy. The same receptor also induces the secretion of important lymphokines.

> Gene Ontology
 
Biological Process GO:0000187 activation of MAPK activity
GO:0001810 regulation of type I hypersensitivity
GO:0001812 positive regulation of type I hypersensitivity
GO:0001819 positive regulation of cytokine production
GO:0001820 serotonin secretion
GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002274 myeloid leukocyte activation
GO:0002275 myeloid cell activation involved in immune response
GO:0002279 mast cell activation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002437 inflammatory response to antigenic stimulus
GO:0002438 acute inflammatory response to antigenic stimulus
GO:0002443 leukocyte mediated immunity
GO:0002444 myeloid leukocyte mediated immunity
GO:0002448 mast cell mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002524 hypersensitivity
GO:0002526 acute inflammatory response
GO:0002673 regulation of acute inflammatory response
GO:0002675 positive regulation of acute inflammatory response
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002703 regulation of leukocyte mediated immunity
GO:0002705 positive regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002708 positive regulation of lymphocyte mediated immunity
GO:0002712 regulation of B cell mediated immunity
GO:0002714 positive regulation of B cell mediated immunity
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0002819 regulation of adaptive immune response
GO:0002821 positive regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002861 regulation of inflammatory response to antigenic stimulus
GO:0002863 positive regulation of inflammatory response to antigenic stimulus
GO:0002864 regulation of acute inflammatory response to antigenic stimulus
GO:0002866 positive regulation of acute inflammatory response to antigenic stimulus
GO:0002883 regulation of hypersensitivity
GO:0002885 positive regulation of hypersensitivity
GO:0002886 regulation of myeloid leukocyte mediated immunity
GO:0002888 positive regulation of myeloid leukocyte mediated immunity
GO:0002889 regulation of immunoglobulin mediated immune response
GO:0002891 positive regulation of immunoglobulin mediated immune response
GO:0006631 fatty acid metabolic process
GO:0006633 fatty acid biosynthetic process
GO:0006636 unsaturated fatty acid biosynthetic process
GO:0006690 icosanoid metabolic process
GO:0006691 leukotriene metabolic process
GO:0006837 serotonin transport
GO:0006887 exocytosis
GO:0007254 JNK cascade
GO:0007257 activation of JUN kinase activity
GO:0015844 monoamine transport
GO:0015850 organic hydroxy compound transport
GO:0016053 organic acid biosynthetic process
GO:0016064 immunoglobulin mediated immune response
GO:0016068 type I hypersensitivity
GO:0017157 regulation of exocytosis
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0019370 leukotriene biosynthetic process
GO:0019722 calcium-mediated signaling
GO:0019724 B cell mediated immunity
GO:0019932 second-messenger-mediated signaling
GO:0031098 stress-activated protein kinase signaling cascade
GO:0031349 positive regulation of defense response
GO:0032103 positive regulation of response to external stimulus
GO:0032147 activation of protein kinase activity
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0032418 lysosome localization
GO:0032604 granulocyte macrophage colony-stimulating factor production
GO:0032632 interleukin-3 production
GO:0032645 regulation of granulocyte macrophage colony-stimulating factor production
GO:0032672 regulation of interleukin-3 production
GO:0032725 positive regulation of granulocyte macrophage colony-stimulating factor production
GO:0032752 positive regulation of interleukin-3 production
GO:0032872 regulation of stress-activated MAPK cascade
GO:0032874 positive regulation of stress-activated MAPK cascade
GO:0033003 regulation of mast cell activation
GO:0033005 positive regulation of mast cell activation
GO:0033006 regulation of mast cell activation involved in immune response
GO:0033008 positive regulation of mast cell activation involved in immune response
GO:0033559 unsaturated fatty acid metabolic process
GO:0033674 positive regulation of kinase activity
GO:0038093 Fc receptor signaling pathway
GO:0038095 Fc-epsilon receptor signaling pathway
GO:0042035 regulation of cytokine biosynthetic process
GO:0042089 cytokine biosynthetic process
GO:0042107 cytokine metabolic process
GO:0042108 positive regulation of cytokine biosynthetic process
GO:0042223 interleukin-3 biosynthetic process
GO:0042253 granulocyte macrophage colony-stimulating factor biosynthetic process
GO:0043299 leukocyte degranulation
GO:0043300 regulation of leukocyte degranulation
GO:0043302 positive regulation of leukocyte degranulation
GO:0043303 mast cell degranulation
GO:0043304 regulation of mast cell degranulation
GO:0043306 positive regulation of mast cell degranulation
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0043506 regulation of JUN kinase activity
GO:0043507 positive regulation of JUN kinase activity
GO:0044283 small molecule biosynthetic process
GO:0045055 regulated exocytosis
GO:0045399 regulation of interleukin-3 biosynthetic process
GO:0045401 positive regulation of interleukin-3 biosynthetic process
GO:0045423 regulation of granulocyte macrophage colony-stimulating factor biosynthetic process
GO:0045425 positive regulation of granulocyte macrophage colony-stimulating factor biosynthetic process
GO:0045576 mast cell activation
GO:0045860 positive regulation of protein kinase activity
GO:0045921 positive regulation of exocytosis
GO:0046328 regulation of JNK cascade
GO:0046330 positive regulation of JNK cascade
GO:0046394 carboxylic acid biosynthetic process
GO:0046456 icosanoid biosynthetic process
GO:0050727 regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0050848 regulation of calcium-mediated signaling
GO:0050850 positive regulation of calcium-mediated signaling
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0051047 positive regulation of secretion
GO:0051403 stress-activated MAPK cascade
GO:0051640 organelle localization
GO:0051656 establishment of organelle localization
GO:0060627 regulation of vesicle-mediated transport
GO:0070302 regulation of stress-activated protein kinase signaling cascade
GO:0070304 positive regulation of stress-activated protein kinase signaling cascade
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0072330 monocarboxylic acid biosynthetic process
GO:1903305 regulation of regulated secretory pathway
GO:1903307 positive regulation of regulated secretory pathway
GO:1903532 positive regulation of secretion by cell
Molecular Function GO:0019763 immunoglobulin receptor activity
GO:0019767 IgE receptor activity
GO:0019863 IgE binding
GO:0019865 immunoglobulin binding
Cellular Component GO:0009897 external side of plasma membrane
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04071 Sphingolipid signaling pathway
hsa04664 Fc epsilon RI signaling pathway
Reactome R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
Summary
SymbolFCER1A
NameFc fragment of IgE, high affinity I, receptor for; alpha polypeptide
Aliases FCE1A; Fc IgE receptor, alpha polypeptide; Fc epsilon RI alpha-chain; Fc-epsilon RI-alpha; high affinity imm ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FCER1A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolFCER1A
NameFc fragment of IgE, high affinity I, receptor for; alpha polypeptide
Aliases FCE1A; Fc IgE receptor, alpha polypeptide; Fc epsilon RI alpha-chain; Fc-epsilon RI-alpha; high affinity imm ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FCER1A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFCER1A
NameFc fragment of IgE, high affinity I, receptor for; alpha polypeptide
Aliases FCE1A; Fc IgE receptor, alpha polypeptide; Fc epsilon RI alpha-chain; Fc-epsilon RI-alpha; high affinity imm ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FCER1A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.5730.217
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0370.962
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.980.11
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1180.84
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.7260.457
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.1850.29
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2470.735
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3320.753
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1910.864
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.0160.413
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0530.54
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-1.0796.3e-05
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FCER1A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFCER1A
NameFc fragment of IgE, high affinity I, receptor for; alpha polypeptide
Aliases FCE1A; Fc IgE receptor, alpha polypeptide; Fc epsilon RI alpha-chain; Fc-epsilon RI-alpha; high affinity imm ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FCER1A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFCER1A
NameFc fragment of IgE, high affinity I, receptor for; alpha polypeptide
Aliases FCE1A; Fc IgE receptor, alpha polypeptide; Fc epsilon RI alpha-chain; Fc-epsilon RI-alpha; high affinity imm ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FCER1A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FCER1A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFCER1A
NameFc fragment of IgE, high affinity I, receptor for; alpha polypeptide
Aliases FCE1A; Fc IgE receptor, alpha polypeptide; Fc epsilon RI alpha-chain; Fc-epsilon RI-alpha; high affinity imm ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FCER1A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFCER1A
NameFc fragment of IgE, high affinity I, receptor for; alpha polypeptide
Aliases FCE1A; Fc IgE receptor, alpha polypeptide; Fc epsilon RI alpha-chain; Fc-epsilon RI-alpha; high affinity imm ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FCER1A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFCER1A
NameFc fragment of IgE, high affinity I, receptor for; alpha polypeptide
Aliases FCE1A; Fc IgE receptor, alpha polypeptide; Fc epsilon RI alpha-chain; Fc-epsilon RI-alpha; high affinity imm ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FCER1A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFCER1A
NameFc fragment of IgE, high affinity I, receptor for; alpha polypeptide
Aliases FCE1A; Fc IgE receptor, alpha polypeptide; Fc epsilon RI alpha-chain; Fc-epsilon RI-alpha; high affinity imm ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FCER1A collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting FCER1A.
ID Name Drug Type Targets #Targets
DB00043OmalizumabBiotechFCER1A, MS4A22
DB00895Benzylpenicilloyl PolylysineSmall MoleculeFCER1A, FCER1G2
DB05797TNX-901Small MoleculeFCER1A1